Chinese General Practice ›› 2023, Vol. 26 ›› Issue (02): 233-240.DOI: 10.12114/j.issn.1007-9572.2022.0579
Special Issue: 心血管最新文章合集; 老年问题最新文章合集
• Medication Guide·Precision Medication • Previous Articles Next Articles
Received:
2022-08-08
Revised:
2022-08-26
Published:
2023-01-15
Online:
2022-08-31
Contact:
LIU Kewei
About author:
通讯作者:
刘科卫
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0579
组别 | 例数 | 年龄(岁) | 性别(男/女) | 体质量(kg) | 冠心病〔n(%)〕 | NYHA心功能分级〔n(%)〕 | 糖尿病〔n(%)〕 | |||
---|---|---|---|---|---|---|---|---|---|---|
SCAD | ACS | Ⅱ级 | Ⅲ级 | Ⅳ级 | ||||||
托伐普坦7.5 mg/d组 | 112 | 91.0±4.6 | 110/2 | 64.8±8.6 | 107(95.5) | 5(4.5) | 44(39.3) | 47(42.0) | 21(18.8) | 42(37.5) |
托伐普坦15.0 mg/d组 | 100 | 91.1±3.4 | 97/3 | 65.0±10.7 | 96(96.0) | 4(4.0) | 44(44.0) | 33(33.0) | 23(23.0) | 41(41.0) |
检验统计量值 | 0.013a | — | 0.013a | — | 1.868 | 0.145 | ||||
P值 | 0.911 | 0.668 | 0.908 | 1.000 | 0.393 | 0.704 | ||||
组别 | 高血压〔n(%)〕 | CKD〔n(%)〕 | 硝酸类药物〔n(%)〕 | 抗血小板药物〔n(%)〕 | β受体阻滞剂〔n(%)〕 | RAS抑制剂〔n(%)〕 | 钙通道阻滞剂〔n(%)〕 | 曲美他嗪〔n(%)〕 | ||
ACEI | ARB | |||||||||
托伐普坦7.5 mg/d组 | 85(75.9) | 28(25.0) | 44(39.3) | 70(62.5) | 75(67.0) | 17(15.2) | 26(23.2) | 35(31.2) | 63(56.2) | |
托伐普坦15.0 mg/d组 | 77(77.0) | 38(38.0) | 32(32.0) | 63(63.0) | 65(65.0) | 18(18.0) | 24(24.0) | 34(34.0) | 47(47.0) | |
检验统计量值 | 0.001 | 3.580 | 0.923 | 0 | 0.024 | 0.380 | 0.078 | 1.459 | ||
P值 | 0.978 | 0.058 | 0.337 | 1.000 | 0.876 | 0.826 | 0.780 | 0.227 | ||
组别 | 口服利尿剂〔n(%)〕 | 呋塞米剂量〔n(%)〕 | 螺内酯剂量〔n(%)〕 | 静脉注射利尿剂〔n(%)〕 | 随访时间〔M(P25,P75),d〕 | |||||
呋塞米 | 螺内酯 | 呋塞米+螺内酯 | ≤20 mg/d | >20 mg/d | ≤20 mg/d | >20 mg/d | ||||
托伐普坦7.5 mg/d组 | 18(16.1) | 26(23.2) | 43(38.4) | 51(45.5) | 10(8.9) | 59(52.7) | 10(8.9) | 50(44.6) | 383.0(168.5,1 108.0) | |
托伐普坦15.0 mg/d组 | 13(13.0) | 25(25.0) | 34(34.0) | 41(41.0) | 6(6.0) | 42(42.0) | 17(17.0) | 53(53.0) | 362.5(142.8,787.8) | |
检验统计量值 | 1.373 | 1.451 | 4.058 | 1.161 | 2.864b | |||||
P值 | 0.712 | 0.484 | 0.131 | 0.281 | 0.091 | |||||
组别 | 托伐普坦应用时间〔M(P25,P75),d〕 | 托伐普坦应用时间〔n(%)〕 | 用药前24 h尿量(ml) | LVEF(%) | 左心室后壁厚度(mm) | 左心室舒张末内径(mm) | 左心房内径(mm) | |||
7~13 d | 14~29 d | ≥30 d | ||||||||
托伐普坦7.5 mg/d组 | 85.0(36.5,275.8) | 10(8.9) | 17(15.2) | 85(75.9) | 1 809.5±652.4 | 56.7±5.2 | 10.1±0.7 | 44.6±4.1 | 38.1±6.6 | |
托伐普坦15.0 mg/d组 | 126.0(56.2,361.5) | 10(10.0) | 10(10.0) | 80(80.0) | 1 621.7±555.4 | 55.4±4.3 | 10.0±0.5 | 44.1±4.7 | 37.2±8.0 | |
检验统计量值 | 2.006b | 1.291 | 4.948a | 2.845a | 0.130a | 0.606a | 0.596a | |||
P值 | 0.064 | 0.524 | 0.027 | 0.088 | 0.719 | 0.437 | 0.441 |
Table 1 Comparison of baseline data between two groups of patients
组别 | 例数 | 年龄(岁) | 性别(男/女) | 体质量(kg) | 冠心病〔n(%)〕 | NYHA心功能分级〔n(%)〕 | 糖尿病〔n(%)〕 | |||
---|---|---|---|---|---|---|---|---|---|---|
SCAD | ACS | Ⅱ级 | Ⅲ级 | Ⅳ级 | ||||||
托伐普坦7.5 mg/d组 | 112 | 91.0±4.6 | 110/2 | 64.8±8.6 | 107(95.5) | 5(4.5) | 44(39.3) | 47(42.0) | 21(18.8) | 42(37.5) |
托伐普坦15.0 mg/d组 | 100 | 91.1±3.4 | 97/3 | 65.0±10.7 | 96(96.0) | 4(4.0) | 44(44.0) | 33(33.0) | 23(23.0) | 41(41.0) |
检验统计量值 | 0.013a | — | 0.013a | — | 1.868 | 0.145 | ||||
P值 | 0.911 | 0.668 | 0.908 | 1.000 | 0.393 | 0.704 | ||||
组别 | 高血压〔n(%)〕 | CKD〔n(%)〕 | 硝酸类药物〔n(%)〕 | 抗血小板药物〔n(%)〕 | β受体阻滞剂〔n(%)〕 | RAS抑制剂〔n(%)〕 | 钙通道阻滞剂〔n(%)〕 | 曲美他嗪〔n(%)〕 | ||
ACEI | ARB | |||||||||
托伐普坦7.5 mg/d组 | 85(75.9) | 28(25.0) | 44(39.3) | 70(62.5) | 75(67.0) | 17(15.2) | 26(23.2) | 35(31.2) | 63(56.2) | |
托伐普坦15.0 mg/d组 | 77(77.0) | 38(38.0) | 32(32.0) | 63(63.0) | 65(65.0) | 18(18.0) | 24(24.0) | 34(34.0) | 47(47.0) | |
检验统计量值 | 0.001 | 3.580 | 0.923 | 0 | 0.024 | 0.380 | 0.078 | 1.459 | ||
P值 | 0.978 | 0.058 | 0.337 | 1.000 | 0.876 | 0.826 | 0.780 | 0.227 | ||
组别 | 口服利尿剂〔n(%)〕 | 呋塞米剂量〔n(%)〕 | 螺内酯剂量〔n(%)〕 | 静脉注射利尿剂〔n(%)〕 | 随访时间〔M(P25,P75),d〕 | |||||
呋塞米 | 螺内酯 | 呋塞米+螺内酯 | ≤20 mg/d | >20 mg/d | ≤20 mg/d | >20 mg/d | ||||
托伐普坦7.5 mg/d组 | 18(16.1) | 26(23.2) | 43(38.4) | 51(45.5) | 10(8.9) | 59(52.7) | 10(8.9) | 50(44.6) | 383.0(168.5,1 108.0) | |
托伐普坦15.0 mg/d组 | 13(13.0) | 25(25.0) | 34(34.0) | 41(41.0) | 6(6.0) | 42(42.0) | 17(17.0) | 53(53.0) | 362.5(142.8,787.8) | |
检验统计量值 | 1.373 | 1.451 | 4.058 | 1.161 | 2.864b | |||||
P值 | 0.712 | 0.484 | 0.131 | 0.281 | 0.091 | |||||
组别 | 托伐普坦应用时间〔M(P25,P75),d〕 | 托伐普坦应用时间〔n(%)〕 | 用药前24 h尿量(ml) | LVEF(%) | 左心室后壁厚度(mm) | 左心室舒张末内径(mm) | 左心房内径(mm) | |||
7~13 d | 14~29 d | ≥30 d | ||||||||
托伐普坦7.5 mg/d组 | 85.0(36.5,275.8) | 10(8.9) | 17(15.2) | 85(75.9) | 1 809.5±652.4 | 56.7±5.2 | 10.1±0.7 | 44.6±4.1 | 38.1±6.6 | |
托伐普坦15.0 mg/d组 | 126.0(56.2,361.5) | 10(10.0) | 10(10.0) | 80(80.0) | 1 621.7±555.4 | 55.4±4.3 | 10.0±0.5 | 44.1±4.7 | 37.2±8.0 | |
检验统计量值 | 2.006b | 1.291 | 4.948a | 2.845a | 0.130a | 0.606a | 0.596a | |||
P值 | 0.064 | 0.524 | 0.027 | 0.088 | 0.719 | 0.437 | 0.441 |
组别 | 例数 | BUN(mmol/L) | Cr(μmol/L) | eGFR〔ml·min-1(1.73 m2) -1〕 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
基线水平 | 治疗后 | t配对值 | P值 | 基线水平 | 治疗后 | t配对值 | P值 | 基线水平 | 治疗后 | t配对值 | P值 | ||
托伐普坦7.5 mg/d组 | 112 | 8.5±5.3 | 8.9±5.2 | 0.784 | 0.441 | 106.6±57.7 | 106.5±50.3 | 1.960 | 0.052 | 35.4±13.5 | 35.6±12.9 | 2.183 | 0.330 |
托伐普坦15.0 mg/d组 | 100 | 8.6±5.2 | 10.3±6.4 | 3.320 | 0.001 | 111.0±54.9 | 121.4±61.6 | 4.700 | <0.001 | 34.9±12.1 | 33.8±12.7 | -1.961 | 0.050 |
t(Z)值 | 0.441 | 0.037 | 0.110 | 1.730 | 0.047 | 0.012 | |||||||
P值 | 0.597 | 0.848 | 2.582 | 0.190 | 0.828 | 0.914 | |||||||
组别 | NT-proBNP〔M(P25,P75),ng/L〕 | cTnI〔M(P25,P75),μg/L〕 | 血钠(mmol/L) | ||||||||||
基线水平 | 治疗后 | Z值 | P值 | 基线水平 | 治疗后 | Z值 | P值 | 基线水平 | 治疗后 | t配对值 | P值 | ||
托伐普坦7.5 mg/d组 | 1 082.0(396.7,2 832.0) | 890.3(321.6,1 764.0) | -1.759 | 0.081 | 0.01(0.01,0.04) | 0.01(0.01,0.04) | 1.273 | 0.206 | 132.2±5.8 | 137.6±4.3 | 7.947 | <0.001 | |
托伐普坦15.0 mg/d组 | 992.8(457.5,3 552.0) | 969.9(310.5,2 529.0) | -2.024 | 0.046 | 0.01(0.01,0.04) | 0.01(0.01,0.05) | 1.083 | <0.001 | 133.2±5.5 | 137.8±5.2 | 8.994 | <0.001 | |
t(Z)值 | 0.906a | 2.391a | 0.314a | 0.950a | 2.912 | 0.269 | |||||||
P值 | 0.341 | 0.122 | 0.576 | 0.330 | 0.090 | 0.605 | |||||||
组别 | 血钾(mmol/L) | 24 h尿量(ml) | ALT〔M(P25,P75),U/L〕 | ||||||||||
基线水平 | 治疗后 | t配对值 | P值 | 基线水平 | 治疗后 | t配对值 | P值 | 基线水平 | 治疗后 | Z值 | P值 | ||
托伐普坦7.5 mg/d组 | 4.2±0.6 | 4.1±0.5 | -0.190 | 0.846 | 1 809.5±652.4 | 2 082.9±589.1 | 4.093 | <0.001 | 16.0(12.0,29.5) | 14.0(9.5,24.5) | -1.756 | 0.177 | |
托伐普坦15.0 mg/d组 | 4.1±0.6 | 4.1±0.5 | 0.390 | 0.715 | 1 621.7±555.4 | 2 034.6±665.8 | 6.852 | <0.001 | 17.0(11.0,25.0) | 14.0(8.0,22.2) | -1.413 | 0.162 | |
t(Z)值 | 1.055 | 0.518 | 4.948 | 3.863 | 1.295a | 1.42a | |||||||
P值 | 0.306 | 0.473 | 0.027 | 0.051 | 0.255 | 0.233 | |||||||
组别 | AST〔M(P25,P75),U/L〕 | AKP〔M(P25,P75),U/L〕 | γ-GT〔M(P25,P75),U/L〕 | ||||||||||
基线水平 | 治疗后 | Z值 | P值 | 基线水平 | 治疗后 | Z值 | P值 | 基线水平 | 治疗后 | Z值 | P值 | ||
托伐普坦7.5 mg/d组 | 16.0(12.0,29.5) | 14.0(9.5,24.5) | -1.417 | 0.251 | 73.0(57.0,91.0) | 72.0(59.0,92.5) | -0.266 | 0.807 | 28.0(22.0,41.0) | 30.0(19.0,47.0) | 0.210 | 0.847 | |
托伐普坦15.0 mg/d组 | 21.0(16.0,31.0) | 20.0(16.5,29.0) | -0.650 | 0.510 | 111.0±54.9 | 121.4±61.6 | 4.700 | 0.812 | 30.0(21.0,50.0) | 34.0(19.8,51.5) | 1.472 | 0.142 | |
t(Z)值 | 0.094a | 0.091a | 3.771 | 0.06 | 0.147a | 0.937a | |||||||
P值 | 0.759 | 0.763 | 0.052 | 0.806 | 0.702 | 0.333 | |||||||
组别 | TBIL〔M(P25,P75),μmol/L〕 | DBIL〔M(P25,P75),μmol/L〕 | IBIL〔M(P25,P75),μmol/L〕 | ||||||||||
基线水平 | 治疗后 | Z值 | P值 | 基线水平 | 治疗后 | Z值 | P值 | 基线水平 | 治疗后 | Z值 | P值 | ||
托伐普坦7.5 mg/d组 | 9.8(7.5,13.4) | 9.8(7.6,14.2) | 1.477 | 0.236 | 3.1(2.3,4.0) | 3.0(2.2,4.6) | 0.678 | 0.547 | 7.0(5.1,9.9) | 6.4(4.9,9.1) | 2.611 | 0.080 | |
托伐普坦15.0 mg/d组 | 10.3(7.8,14.7) | 10.8(8.0,15.8) | 1.812 | 0.072 | 3.1(2.1,4.5) | 3.8(2.5,6.1) | 1.773 | 0.084 | 7.2(5.4,9.8) | 6.7(4.7,9.5) | -0.670 | 0.493 | |
t(Z)值 | 0.547a | 1.171a | 0.150a | 4.819a | 0.047a | 0.035a | |||||||
P值 | 0.459 | 0.279 | 0.699 | 0.058 | 0.829 | 0.852 |
Table 2 Comparison of laboratory indices before and after tolvaptan treatment in two groups
组别 | 例数 | BUN(mmol/L) | Cr(μmol/L) | eGFR〔ml·min-1(1.73 m2) -1〕 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
基线水平 | 治疗后 | t配对值 | P值 | 基线水平 | 治疗后 | t配对值 | P值 | 基线水平 | 治疗后 | t配对值 | P值 | ||
托伐普坦7.5 mg/d组 | 112 | 8.5±5.3 | 8.9±5.2 | 0.784 | 0.441 | 106.6±57.7 | 106.5±50.3 | 1.960 | 0.052 | 35.4±13.5 | 35.6±12.9 | 2.183 | 0.330 |
托伐普坦15.0 mg/d组 | 100 | 8.6±5.2 | 10.3±6.4 | 3.320 | 0.001 | 111.0±54.9 | 121.4±61.6 | 4.700 | <0.001 | 34.9±12.1 | 33.8±12.7 | -1.961 | 0.050 |
t(Z)值 | 0.441 | 0.037 | 0.110 | 1.730 | 0.047 | 0.012 | |||||||
P值 | 0.597 | 0.848 | 2.582 | 0.190 | 0.828 | 0.914 | |||||||
组别 | NT-proBNP〔M(P25,P75),ng/L〕 | cTnI〔M(P25,P75),μg/L〕 | 血钠(mmol/L) | ||||||||||
基线水平 | 治疗后 | Z值 | P值 | 基线水平 | 治疗后 | Z值 | P值 | 基线水平 | 治疗后 | t配对值 | P值 | ||
托伐普坦7.5 mg/d组 | 1 082.0(396.7,2 832.0) | 890.3(321.6,1 764.0) | -1.759 | 0.081 | 0.01(0.01,0.04) | 0.01(0.01,0.04) | 1.273 | 0.206 | 132.2±5.8 | 137.6±4.3 | 7.947 | <0.001 | |
托伐普坦15.0 mg/d组 | 992.8(457.5,3 552.0) | 969.9(310.5,2 529.0) | -2.024 | 0.046 | 0.01(0.01,0.04) | 0.01(0.01,0.05) | 1.083 | <0.001 | 133.2±5.5 | 137.8±5.2 | 8.994 | <0.001 | |
t(Z)值 | 0.906a | 2.391a | 0.314a | 0.950a | 2.912 | 0.269 | |||||||
P值 | 0.341 | 0.122 | 0.576 | 0.330 | 0.090 | 0.605 | |||||||
组别 | 血钾(mmol/L) | 24 h尿量(ml) | ALT〔M(P25,P75),U/L〕 | ||||||||||
基线水平 | 治疗后 | t配对值 | P值 | 基线水平 | 治疗后 | t配对值 | P值 | 基线水平 | 治疗后 | Z值 | P值 | ||
托伐普坦7.5 mg/d组 | 4.2±0.6 | 4.1±0.5 | -0.190 | 0.846 | 1 809.5±652.4 | 2 082.9±589.1 | 4.093 | <0.001 | 16.0(12.0,29.5) | 14.0(9.5,24.5) | -1.756 | 0.177 | |
托伐普坦15.0 mg/d组 | 4.1±0.6 | 4.1±0.5 | 0.390 | 0.715 | 1 621.7±555.4 | 2 034.6±665.8 | 6.852 | <0.001 | 17.0(11.0,25.0) | 14.0(8.0,22.2) | -1.413 | 0.162 | |
t(Z)值 | 1.055 | 0.518 | 4.948 | 3.863 | 1.295a | 1.42a | |||||||
P值 | 0.306 | 0.473 | 0.027 | 0.051 | 0.255 | 0.233 | |||||||
组别 | AST〔M(P25,P75),U/L〕 | AKP〔M(P25,P75),U/L〕 | γ-GT〔M(P25,P75),U/L〕 | ||||||||||
基线水平 | 治疗后 | Z值 | P值 | 基线水平 | 治疗后 | Z值 | P值 | 基线水平 | 治疗后 | Z值 | P值 | ||
托伐普坦7.5 mg/d组 | 16.0(12.0,29.5) | 14.0(9.5,24.5) | -1.417 | 0.251 | 73.0(57.0,91.0) | 72.0(59.0,92.5) | -0.266 | 0.807 | 28.0(22.0,41.0) | 30.0(19.0,47.0) | 0.210 | 0.847 | |
托伐普坦15.0 mg/d组 | 21.0(16.0,31.0) | 20.0(16.5,29.0) | -0.650 | 0.510 | 111.0±54.9 | 121.4±61.6 | 4.700 | 0.812 | 30.0(21.0,50.0) | 34.0(19.8,51.5) | 1.472 | 0.142 | |
t(Z)值 | 0.094a | 0.091a | 3.771 | 0.06 | 0.147a | 0.937a | |||||||
P值 | 0.759 | 0.763 | 0.052 | 0.806 | 0.702 | 0.333 | |||||||
组别 | TBIL〔M(P25,P75),μmol/L〕 | DBIL〔M(P25,P75),μmol/L〕 | IBIL〔M(P25,P75),μmol/L〕 | ||||||||||
基线水平 | 治疗后 | Z值 | P值 | 基线水平 | 治疗后 | Z值 | P值 | 基线水平 | 治疗后 | Z值 | P值 | ||
托伐普坦7.5 mg/d组 | 9.8(7.5,13.4) | 9.8(7.6,14.2) | 1.477 | 0.236 | 3.1(2.3,4.0) | 3.0(2.2,4.6) | 0.678 | 0.547 | 7.0(5.1,9.9) | 6.4(4.9,9.1) | 2.611 | 0.080 | |
托伐普坦15.0 mg/d组 | 10.3(7.8,14.7) | 10.8(8.0,15.8) | 1.812 | 0.072 | 3.1(2.1,4.5) | 3.8(2.5,6.1) | 1.773 | 0.084 | 7.2(5.4,9.8) | 6.7(4.7,9.5) | -0.670 | 0.493 | |
t(Z)值 | 0.547a | 1.171a | 0.150a | 4.819a | 0.047a | 0.035a | |||||||
P值 | 0.459 | 0.279 | 0.699 | 0.058 | 0.829 | 0.852 |
变量 | 单因素分析 | 多因素分析 | ||
---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | |
托伐普坦15.0 mg/d组 | 1.70(1.18,2.46) | 0.005 | 2.04(1.38,3.01) | 0.001 |
年龄 | 1.03(0.99,1.07) | 0.195 | 1.02(0.97,1.07) | 0.523 |
NYHA(Ⅲ级) | 1.23(0.81,1.85) | 0.336 | 1.16(0.73,1.85) | 0.536 |
NYHA(Ⅳ级) | 2.13(1.36,3.35) | 0.001 | 2.15(1.21,3.83) | 0.009 |
CKD | 1.06(0.71,1.57) | 0.784 | 1.02(0.61,1.69) | 0.954 |
β受体阻滞剂 | 0.92(0.63,1.33) | 0.644 | 0.89(0.6,1.31) | 0.562 |
RAS抑制剂 | 0.64(0.43,0.93) | 0.021 | 0.72(0.48,1.07) | 0.105 |
口服呋塞米 | 1.91(1.05,3.48) | 0.034 | 2.27(1.08,4.76) | 0.030 |
螺内酯 | 1.19(0.68,2.07) | 0.552 | 1.72(0.93,3.19) | 0.086 |
呋塞米+螺内酯 | 1.82(1.11,3.00) | 0.018 | 2.05(1.15,3.66) | 0.015 |
ALB | 0.94(0.9,0.98) | 0.002 | 0.95(0.90,1.00) | 0.035 |
lgNTproBNP | 1.55(1.15,2.08) | 0.004 | 1.26(0.83,1.92) | 0.285 |
eGFR | 0.87(0.85,1.08) | 0.348 | 0.99(0.97,1.02) | 0.564 |
Table 3 Cox risk regression analysis of two doses of tolvaptan and all-cause mortality in elderly patients with heart failure
变量 | 单因素分析 | 多因素分析 | ||
---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | |
托伐普坦15.0 mg/d组 | 1.70(1.18,2.46) | 0.005 | 2.04(1.38,3.01) | 0.001 |
年龄 | 1.03(0.99,1.07) | 0.195 | 1.02(0.97,1.07) | 0.523 |
NYHA(Ⅲ级) | 1.23(0.81,1.85) | 0.336 | 1.16(0.73,1.85) | 0.536 |
NYHA(Ⅳ级) | 2.13(1.36,3.35) | 0.001 | 2.15(1.21,3.83) | 0.009 |
CKD | 1.06(0.71,1.57) | 0.784 | 1.02(0.61,1.69) | 0.954 |
β受体阻滞剂 | 0.92(0.63,1.33) | 0.644 | 0.89(0.6,1.31) | 0.562 |
RAS抑制剂 | 0.64(0.43,0.93) | 0.021 | 0.72(0.48,1.07) | 0.105 |
口服呋塞米 | 1.91(1.05,3.48) | 0.034 | 2.27(1.08,4.76) | 0.030 |
螺内酯 | 1.19(0.68,2.07) | 0.552 | 1.72(0.93,3.19) | 0.086 |
呋塞米+螺内酯 | 1.82(1.11,3.00) | 0.018 | 2.05(1.15,3.66) | 0.015 |
ALB | 0.94(0.9,0.98) | 0.002 | 0.95(0.90,1.00) | 0.035 |
lgNTproBNP | 1.55(1.15,2.08) | 0.004 | 1.26(0.83,1.92) | 0.285 |
eGFR | 0.87(0.85,1.08) | 0.348 | 0.99(0.97,1.02) | 0.564 |
因变量 | 自变量 | 未调整模型 | 模型1 | 模型2 | 模型3 | ||||
---|---|---|---|---|---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | ||
全因死亡 | 托伐普坦7.5 mg/d组 | 1.00 | — | 1.00 | 1.00 | — | 1 | — | |
托伐普坦15.0 mg/d组 | 1.70(1.18,2.46) | 0.005 | 1.73(1.19,2.50) | 0.004 | 1.76(1.22,2.60) | 0.003 | 2.03(1.34,2.99) | 0.001 | |
心血管死亡 | 托伐普坦7.5 mg/d组 | 1.00 | — | 1.00 | 1.00 | — | 1 | — | |
托伐普坦15.0 mg/d组 | 2.48(1.40,4.39) | 0.002 | 2.50(1.41,4.45) | 0.002 | 2.75(1.52,4.96) | 0.001 | 2.51(1.40,4.50) | 0.002 |
Table 4 Cox proportional risk regression models for the effect of two doses of tolvaptan on all-cause mortality and cardiovascular mortality
因变量 | 自变量 | 未调整模型 | 模型1 | 模型2 | 模型3 | ||||
---|---|---|---|---|---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | ||
全因死亡 | 托伐普坦7.5 mg/d组 | 1.00 | — | 1.00 | 1.00 | — | 1 | — | |
托伐普坦15.0 mg/d组 | 1.70(1.18,2.46) | 0.005 | 1.73(1.19,2.50) | 0.004 | 1.76(1.22,2.60) | 0.003 | 2.03(1.34,2.99) | 0.001 | |
心血管死亡 | 托伐普坦7.5 mg/d组 | 1.00 | — | 1.00 | 1.00 | — | 1 | — | |
托伐普坦15.0 mg/d组 | 2.48(1.40,4.39) | 0.002 | 2.50(1.41,4.45) | 0.002 | 2.75(1.52,4.96) | 0.001 | 2.51(1.40,4.50) | 0.002 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
中国医师协会心力衰竭专业委员会,中华心力衰竭和心肌病杂志编辑委员会. 心力衰竭容量管理中国专家建议[J]. 中华心力衰竭和心肌病杂志(中英文),2018,2(1):8-16.
|
[6] |
|
[7] |
中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018 [J] . 中华心血管病杂志,2018,46(10):760-789. DOI:10.3760/cma.j.issn.0253-3758.2018.10.004.
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
徐先静,黄改荣,刘雪亚,等. 托伐普坦治疗75岁及以上难治性心力衰竭患者的临床疗效观察[J]. 中华老年医学杂志,2020,39(9):1038-1041.
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[1] | XUE Chongxiang, LU Xingyu, LIU Zhening, DONG Huijing, ZHENG Yumin, CUI Huijuan. Dynamic Monitoring of Gene Changes and Its Prognostic Value in Lung Cancer Patients [J]. Chinese General Practice, 2023, 26(36): 4527-4534. |
[2] | CUI Xiaona, FENG Ruixia, HAN Yupeng, ZHOU Yaoyao, LIU Xiaojun, LI Jianchao. A Comparative Study on Clinical Effects of Combined Auxiliary Sequence of VA-ECMO and IABP on Acute Myocardial Infarction Complicated with Cardiogenic Shock [J]. Chinese General Practice, 2023, 26(35): 4439-4445. |
[3] | ZHANG Jin, DING Zhiguo, QI Shuo, LI Ying, LI Weiqiang, ZHANG Yuanyuan, ZHOU Tong. Relationship between Serum Thyroid Hormone Levels and Prognosis during Hospitalization in Heart Failure Patients [J]. Chinese General Practice, 2023, 26(33): 4125-4129. |
[4] | ZHANG Siyu, ZHOU Yuqiu, DU Xiaohui, WANG Zhengjun. Advances in Duration of Untreated Psychosis and Its Early Intervention [J]. Chinese General Practice, 2023, 26(33): 4110-4117. |
[5] | MENG Jiangtao, YANG Siyu, SUN Lei, LEI Ruining, ZHAO Xiaoxia. Advances in the Prognostic Value of Diffusion Tensor Imaging with Motor Evoked Potential for Motor Function in Cerebral Infarction Patients with Hemiplegia [J]. Chinese General Practice, 2023, 26(32): 4098-4102. |
[6] | ZHANG Peng, GAO Ying, YANG Hongxi, WAN Chunxiao. Association between Serum Uric Acid Level and the Risk of Chronic Kidney Disease among the Elderly in Longevity Areas of China [J]. Chinese General Practice, 2023, 26(31): 3884-3889. |
[7] | CHEN Xi, ZHANG Juan, LI Lin, ZHANG Jiaqi, WU Yaoli, GUO Hui, WANG Chaoqun. Association between Physical Activity and Risk of All-cause Mortality in Middle-aged and Elderly People in China: a Prospective Cohort Study [J]. Chinese General Practice, 2023, 26(31): 3890-3895. |
[8] | YAN Ke, WEI Wanyi, LI Shuguang, YAO Weinan, DONG Jing, WANG Xiaobin, ZHANG Xueyuan, YANG Jie, SHEN Wenbin, ZHU Shuchai. Effect of Consolidation Chemotherapy on Prognosis of StageⅡ-Ⅲ Esophageal Squamous Cell Carcinoma Patients Treated with Definitive Concurrent Chemotherapy and Radio-therapy [J]. Chinese General Practice, 2023, 26(30): 3772-3779. |
[9] | YAN Ke, WEI Wanyi, DENG Wenzhao, SHEN Wenbin, LI Shuguang, DU Xingyu, ZHANG Xueyuan, YANG Jie, ZHU Shuchai. Long-term Prognosis Analysis and Influencing Factors of Concurrent Chemotherapy and Radio-therapy for Cervical and Upper Thoracic Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2023, 26(30): 3785-3790. |
[10] | SHI Xiaoqi, LUO Nandu, HUANG Jiaojiao, DU Zuochen, HUANG Pei, CAO Xiuli, CHEN Yan, HE Zhixu. Correlation between Aspartate Aminotransferase/Alanine Aminotransferase and Prognosis of Hemophagocytic Lymphohistiocytosis in Children [J]. Chinese General Practice, 2023, 26(30): 3801-3808. |
[11] | HE Yingmei, JIA Xue, ZHU Guojun, LIU Bing. Effect of Serum Uric Acid Longitudinal Trajectory on New-onset Hypertriglyceridemia: a Prospective Cohort Study [J]. Chinese General Practice, 2023, 26(29): 3636-3639. |
[12] | ZHANG Yunsheng, ZHANG Peng, JIN Yujing, GAO Ying. Association of Blood Pressure Level with the Risk of Chronic Kidney Disease among the Elderly in Longevity Areas of China [J]. Chinese General Practice, 2023, 26(28): 3502-3506. |
[13] | XU Zhe, ZHANG Jinxia, ZHANG Xiuhong, XIE Kaihong. Relationship between Sleep Duration and All-cause Mortality in Middle-aged and Older Adults [J]. Chinese General Practice, 2023, 26(28): 3507-3512. |
[14] | TANG Shilan, XIE Kexin, LIU Lingyu, QI Tiantian, YANG Yansui. Advances in Rehabilitation Outcomes and Care in Patients with Prolonged Disorders of Consciousness [J]. Chinese General Practice, 2023, 26(27): 3342-3348. |
[15] | WEI Lan, HUANG Yue, SONG Yanan, HOU Lihong, WANG Yani, PAN Dongchen, FEI Xiaolu. Investigation on Platform for Evaluation Management and Consultation Services of Polypharmacy among Older Patients Needs of Healthcare Professionals [J]. Chinese General Practice, 2023, 26(25): 3157-3162. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||